Speaker Details

Christopher John Sayed, MD, FAAD

Christopher John Sayed, MD, FAAD

SESSIONS

U009 In Office Surgical Techniques for the Treatment of Moderate to Severe Hidradenitis Suppurativa (HS)
Mar 27, 2026 • 7:30 AM - 8:30 AM • Mile High 4D
S030 A New Paradigm in the Management of the Hidradenitis Suppurativa Disease Spectrum
Mar 28, 2026 • 9:00 AM - 12:00 PM • Mile High 2B
F058 How to Approach Challenges in Hidradenitis Suppurativa Management: Strategies to Optimize Use of HS Therapies
Mar 29, 2026 • 1:00 PM - 3:00 PM • Bluebird 1B

DISCLOSURES

AbbVie – Advisory Board(Fees), Investigator(Fees), Speaker(Fees); Alumis – Consultant(Fees); AstraZeneca – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); Elasmogen – Consultant (1099 relationship)(Fees); Eli Lilly – Stockholder Public Company(Stock); Incyte – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); InflaRx – Consultant(Fees), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Investigator(Fees), Speaker(Honoraria); Sandoz Pharmaceuticals AG – Consultant (1099 relationship)(Honoraria); Sanofi – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding);